Orgenesis Inc. Announces Pricing of 3.7 Million Registered Direct Offering

ORGSDelisted Stock  USD 1.22  0.31  20.26%   
Slightly above 62% of Orgenesis' investor base is looking to short. The analysis of overall sentiment of trading Orgenesis otc stock suggests that many investors are alarmed at this time. Orgenesis' investing sentiment can be driven by a variety of factors including economic data, Orgenesis' earnings reports, geopolitical events, and overall market trends.
Orgenesis otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Orgenesis daily returns and investor perception about the current price of Orgenesis as well as its diversification or hedging effects on your existing portfolios.
  
GERMANTOWN, Md., Feb. 23, 2023 -- Orgenesis, Inc. , a global biotech company working to unlock the full potential of cell and gene therapies, today

Read at benzinga.com
benzinga news
  

Orgenesis Fundamental Analysis

We analyze Orgenesis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Orgenesis is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Orgenesis Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orgenesis otc stock to make a market-neutral strategy. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics with similar companies.

Peers

Orgenesis Related Equities

ACRVAcrivon Therapeutics,   16.34   
0%
100.0%
DSGNDesign Therapeutics   7.94   
0%
48.0%
KTTAPasithea Therapeutics   6.48   
0%
39.0%
LIXTLixte Biotechnology   4.95   
0%
30.0%
QNRXQuoin Pharmaceuticals   4.48   
0%
27.0%
INDPIndaptus Therapeutics   3.53   
0%
21.0%
ANTXAN2 Therapeutics   2.16   
0%
13.0%
ACHLAchilles Therapeutics   1.75   
0%
10.0%
RZLTRezolute   1.75   
0%
10.0%
TNGXTango Therapeutics   0.64   
0%
3.0%
NRBONeurobo Pharmaceuticals   0.00   
0%
0%
AVTEAerovate Therapeutics   0.37   
2.0%
0%
ADAGAdagene   1.94   
11.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Orgenesis OTC Stock

If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals